-
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Transgenomic Inc. (OTCBB:TBIO), Omaha, Neb. Business: Diagnostic Transgenomic launched worldwide the CRC RAScan test to screen patients with metastatic colorectal cancer (…
Published on 5/20/2013
-
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Zhejiang Beta Pharma Co. Ltd., Hang-Zhou, China Business: Cancer Amgen and Zhejiang Beta formed a JV - Amgen-Beta Pharmaceuticals Co. Ltd. - to commercialize Amgen's …
Published on 5/20/2013
-
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Business: Infectious Valeant said it will not launch efinaconazole to treat …
Published on 5/20/2013
-
Igdrasol Inc., Fountain Valley, Calif. Samyang Corp. (KSE:000070), Seoul, South Korea Sorrento Therapeutics Inc. (OTCBB:SRNE), San Diego, Calif. Business: Cancer Samyang's Samyang Biopharmaceuticals Corp. subsidiary …
Published on 5/20/2013
-
Savient Pharmaceuticals Inc. (NASDAQ:SVNT), Bridgewater, N.J. Business: Endocrine/Metabolic Savient said in its 1Q13 earnings that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. …
Published on 5/20/2013
-
Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Business: Endocrine/Metabolic Vivus said obesity drug Qsymia phentermine/topiramate was added to the national …
Published on 5/20/2013
-
Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Tri-Luma cream in the U.S. to treat moderate to severe melisma of the face for up to eight weeks. Tri-Luma is a topical combination of …
Published on 2/18/2013
-
Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Business: Endocrine/Metabolic Hisamitsu's Noven Pharmaceuticals Inc. subsidiary launched Minivelle estradiol transdermal system in the U.S. to …
Published on 2/18/2013
-
Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Business: Endocrine/Metabolic On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a …
Published on 2/18/2013
-
Innovus Pharmaceuticals Inc. (OTCBB:INNV), San Diego, Calif. Prospector Capital Partners II LLC, San Diego, Calif. Business: Gastrointestinal, Dermatology Innovus signed a binding term sheet to acquire nine prescription…
Published on 2/18/2013
-
Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Saladax Biomedical Inc., Bethlehem, Pa. Business: Diagnostic Saladax said Myriad will return North American rights to its My5-FU diagnostic test following a …
Published on 2/18/2013
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk said it will launch diabetes drug Tresiba insulin degludec in Japan "shortly after" the drug is listed on Japan's …
Published on 2/18/2013
-
Reckitt Benckiser Group plc (LSE:RB), Slough, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pharmaceuticals Reckitt Benckiser will acquire exclusive commercialization and distribution rights to OTC …
Published on 2/18/2013
-
American International Biotechnology LLC, Richmond, Va. Business: Diagnostic The company launched its LDT asparaginase assay in the U.S. and Canada. The assay measures L-asparaginase levels in patients receiving …
Published on 2/11/2013
-
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Endocrine/Metabolic, Infectious Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012 that it launched three products. Astellas said that …
Published on 2/11/2013
-
Biotest AG (Xetra:BIO), Dreieich, Germany Business: Autoimmune, Diagnostic Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency …
Published on 2/11/2013
-
Dyax Corp. (NASDAQ:DYAX), Burlington, Mass. Novellus Biopharma AG, Switzerland Business: Inflammation Dyax and Novellus partnered to develop and commercialize Kalbitor ecallantide in select regions in Latin America to …
Published on 2/11/2013
-
Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Pharmasyntez, Irkutsk, Russia Business: Cancer Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in …
Published on 2/11/2013
-
Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom said it expanded the range of chromosomal abnormalities reported by the MaterniT21 Plus laboratory-developed test (LDT) to include fetal sex …
Published on 2/11/2013
-
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Business: Neurology Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of partial seizures in adults and …
Published on 2/11/2013
-
Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Amarin said it launched Vascepa icosapent ethyl in the U.S. as an adjunct to diet to reduce triglyceride levels in adults with severe …
Published on 2/4/2013
-
Arup Laboratories, Salt Lake City, Utah Counsyl Inc., South San Francisco, Calif. Business: Diagnostic Arup partnered with Counsyl to include the Counsyl Test in Arup's pre-pregnancy and early pregnancy genetic test …
Published on 2/4/2013
-
D&A Pharma, Paris, France Imaxio S.A., Saint-Beauzire, France Business: Endocrine/Metabolic D&A granted Imaxio rights to congenital metabolic disease drug Trolovol d-penicillamine in France. The chelator is marketed in …
Published on 2/4/2013
-
Epigenomics AG (Xetra:ECX), Berlin, Germany Predictive Biosciences Inc., Lexington, Mass. Business: Diagnostic The partners said Predictive Biosciences launched a biopsy test to diagnose prostate cancer in the U.S. that…
Published on 2/4/2013
-
Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Business: Cancer Exelixis launched Cometriq cabozantinib in the U.S. to treat progressive, metastatic medullary thyroid cancer (MTC). The wholesale acquisition …
Published on 2/4/2013